Erik Harris
CIK 1780113 · EVP & Chief Commercial Officer · last filed 2026-04-20
Erik Harris is an EVP & Chief Commercial Officer who has filed 31 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing, for RARE, was dated Apr 20, 2026. Across all open-market trades the lifetime net is −$2.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.34M
4
31
-$2.66M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RARE | EVP & Chief Commercial Officer | 118,410 | $24.35 | $2.88M | -$2.66M | 25 | 2026-04-20 |
| RZLT | Director | 21,000 | $4.00 | $84.0K | $0 | 2 | 2025-11-21 |
| Inozyme Pharma, Inc. (INZY) Delisted | Director | — | $4.00 | — | $0 | 1 | 2024-10-07 |
| DNLI | Director | 17,052 | $21.66 | $369.3K | $0 | 3 | 2024-06-04 |
Recent Filings
31 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-20 | RARE | Grant (A) | +28,895 | $0 | EDGAR |
| 2026-03-03 | RARE | Mixed | +1,104 | -$240.3K | EDGAR |
| 2025-11-21 | RZLT | Grant (A) | +21,000 | $0 | EDGAR |
| 2025-03-26 | RZLT | Grant (A) | — | $0 | EDGAR |
| 2025-03-04 | RARE | Mixed | +20,153 | -$635.8K | EDGAR |
| 2024-10-07 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-04 | DNLI | Grant (A) | +5,967 | $0 | EDGAR |
| 2024-03-05 | RARE | Mixed | +15,589 | -$256.3K | EDGAR |
| 2023-09-06 | RARE | Sell (S) | −6,000 | -$227.8K | EDGAR |
| 2023-06-21 | RARE | Sell (S) | −305 | -$14.7K | EDGAR |